+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


North American Diagnostic Biomarker Market 2019-2025

  • ID: 4991534
  • Report
  • January 2020
  • Region: North America
  • Orion Market Research Private Limited


  • Abbott Laboratories Inc.
  • Beckman Coulter Inc.
  • Empire Genomics, LLC
  • GeneNews Ltd.
  • Inova Diagnostics, Inc.
  • Myriad Genetics, Inc.
North American Diagnostic Biomarker Market Size, Share & Trends Analysis Report by Diagnostic Technique (ELISA, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle-Enhanced Turbidimetric Immunoassay, and Others), By Application (Oncology, Cardiology, Neurology, Nephrology, and Others), and Forecast 2019-2025.

The North American diagnostic biomarker market is estimated to grow significantly at a CAGR of over 13% during the forecast period. Factors that are contributing significantly in the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. Moreover, the market growth is attributed to the rising prevalence of cancer, CVDs, and chronic diseases. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the North American region.

North America is one of the strongest economies globally, comprising around 23.3% of the world economy as per the International Monetary Fund in 2017. According to data from OECD, in 2016 the US spent almost 17.2% of GDP on healthcare expenditure, whereas Canada spent 10.6% of GDP on healthcare. Accordingly, the healthcare expenditure rate of the US is more than that of Canada, as the US government invests more in R&D. Furthermore, socio-economic factors such as health, income, population base creates more business opportunity in the US as compared to Canada.

The North American diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of researches is going on for finding diagnostic biomarkers for various types of cancer so that early detection can be done.

The major players in the North American diagnostic biomarker market include Abbott Laboratories, Inc., Thermo Fisher Scientific, inc., Becton Dickinson and Co., Pfizer Inc., Quest Diagnostic Inc., and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments. For instance, Astute Inc. in March 2017, entered into two agreements to expand global access to the NephroCheck Test. The company expanded its agreement with Ortho Clinical Diagnostics to add more countries under a new European distribution deal. In addition, the company established a distribution agreement with bioMérieux in the US for promoting the NephroCheck Test of Astute Medical on Astute140 Meter in the US.

Research Methodology

The market study of the North American diagnostic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. North American Diagnostic Biomarker Market Research and Analysis by Diagnostic Technique
2. North American Diagnostic Biomarker Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the North American Diagnostic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American Diagnostic Biomarker Market.
  • Insights about market determinants which are stimulating the North American Diagnostic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown


  • Abbott Laboratories Inc.
  • Beckman Coulter Inc.
  • Empire Genomics, LLC
  • GeneNews Ltd.
  • Inova Diagnostics, Inc.
  • Myriad Genetics, Inc.

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. North American Diagnostic Biomarker Market by Diagnostic Technique
5.1.1. ELISA
5.1.2. Colorimetric Assay
5.1.3. Liquid Chromatography-Mass Spectrometry
5.1.4. Particle-Enhanced Turbidimetric Immunoassay
5.1.5. Others
5.2. North American Diagnostic Biomarker Market by Application
5.2.1. Oncology
5.2.2. Cardiology
5.2.3. Neurology
5.2.4. Nephrology
5.2.5. Others
6. Regional Analysis
6.1. United States
6.2. Canada
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. Acumen Pharmaceuticals, Inc.
7.3. Agilent Technologies, Inc.
7.4. Astute Medical, Inc.
7.5. Banyan Biomarkers, Inc.
7.6. Beckman Coulter Inc.
7.7. Becton, Dickson and Co.
7.8. Biodesix, Inc.
7.9. Bio-Rad Laboratories, Inc.
7.10. Critical Care Diagnostics, Inc.
7.11. Empire Genomics, LLC
7.12. Enzo Life Sciences, Inc.
7.13. Foundation Medicine, Inc.
7.14. GeneNews Ltd.
7.15. Hologic, Inc.
7.16. Illumina, Inc.
7.17. Inova Diagnostics, Inc.
7.18. Luminex Corp.
7.19. Merck and Co., Inc.
7.20. Myriad Genetics, Inc.
7.21. NanoString Technologies, Inc.
7.22. NeoGenomics, Inc.
7.23. Pacific Biomarker Inc.
7.24. Pfizer, Inc.
7.25. Pliant Therapeutics, Inc.
7.26. Quest Diagnostics Inc.
7.27. Response Biomedical Corp.
7.28. Signosis Inc.
7.29. Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Acumen Pharmaceuticals, Inc.
  • Agilent Technologies, Inc.
  • Astute Medical, Inc.
  • Banyan Biomarkers, Inc.
  • Beckman Coulter Inc.
  • Becton, Dickson and Co.
  • Biodesix, Inc.
  • Bio-Rad Laboratories, Inc.
  • Critical Care Diagnostics, Inc.
  • Empire Genomics, LLC
  • Enzo Life Sciences, Inc.
  • Foundation Medicine, Inc.
  • GeneNews Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Inova Diagnostics, Inc.
  • Luminex Corp.
  • Merck and Co., Inc.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • NeoGenomics, Inc.
  • Pacific Biomarker Inc.
  • Pfizer, Inc.
  • Pliant Therapeutics, Inc.
  • Quest Diagnostics Inc.
  • Response Biomedical Corp.
  • Signosis Inc.
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown